Guangji pharmaceutical: 163.9% - 243.07% increase in net profit in the first half of the year
Guangji pharmaceutical disclosed the half year performance forecast of 2021, and it is expected to achieve the net profit of RMB 50 million to RMB 65 million belonging to the shareholders of the listed company from January to June 2021, with a year-on-year growth of 163.90% - 243.07%. During the reporting period, the sales volume of pharmaceutical grade VB2 and VB6 products increased.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
Rehabilitation Robots Analysis
The rehabilitation robot can provide effective assistive training, reduce the number of carers needed, and ease the contradiction between supply and demand in rehabilitation resources. The industry developed rapidly around 2016 and has now entered an expansion period. At the same time, robots of some enterprises have obtained medical device licenses, and rehabilitation robots in the future will have more possibilities in application scenarios with huge growth space.
Oct 26, 2022 05:09 PM
Briefing Jun 12, 2022 04:33 PM
· Industrials
CHUANHENG shares: mining depth of Xiaoba phosphorus mine mining right increased by 300m
Dec 11, 2023 08:49 PM
May 11, 2023 05:07 PM
Dec 28, 2021 06:19 PM
Jun 29, 2021 11:48 PM
Briefing Jun 10, 2022 09:48 PM
Singaporean Prime Minister Lee Hsien Loong meets with weifenghe
Briefing Jun 10, 2022 11:09 AM
· Consumer Staples
Ministry of agriculture and rural areas: strictly control the conversion of cultivated land to other agricultural land
The popular Chinese stocks in the US stock market fell before the market, and Alibaba fell nearly 5%
Most of the popular Chinese stocks rose before the US market, and the B station rose by more than 7%
Briefing Jun 07, 2022 09:05 PM
Shanghai Municipal Bureau of human resources and social security: international students from the world's top 50 universities can directly settle in Shanghai
Briefing Jun 01, 2022 10:34 AM
· Consumer Staples
China Merchants Securities: maintain the "recommended" rating on Alibaba and look forward to the development prospect of global business
Briefing May 27, 2022 01:53 PM
· Consumer Staples
Citigroup lowered the target price of Alibaba's US shares from US $177 to US $176.
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
Chinese Cuisine Brand YGF Malatang Ventures into Brazil
Yesterday 02:21 PM
Insight
In-depth